A Phase IIb Study of ABT‐494, a Selective JAK‐1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–Tumor Necrosis Factor Therapy

OBJECTIVE: To compare the efficacy and safety of ABT‐494, a novel selective JAK‐1 inhibitor, with placebo in patients with moderate‐to‐severe rheumatoid arthritis (RA) and an inadequate response or intolerance to at least 1 anti–tumor necrosis factor (anti‐TNF) agent. METHODS: In this 12‐week, doubl...

Descripción completa

Detalles Bibliográficos
Autores principales: Kremer, Joel M., Emery, Paul, Camp, Heidi S., Friedman, Alan, Wang, Li, Othman, Ahmed A., Khan, Nasser, Pangan, Aileen L., Jungerwirth, Steven, Keystone, Edward C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5132116/
https://www.ncbi.nlm.nih.gov/pubmed/27389975
http://dx.doi.org/10.1002/art.39801

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5132116/
https://www.ncbi.nlm.nih.gov/pubmed/27389975
http://dx.doi.org/10.1002/art.39801

Ejemplares similares